WEC
AXDX

Winslow Evans & Crocker’s Accelerate Diagnostics AXDX Stock Holding History

Winslow Evans & Crocker’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$9K Buy
+118
New +$10.6K ﹤0.01% 959
2019
Q2 		– Sell
-6
Closed -$2K – 1152
2019
Q1 		$2K Buy
+6
New +$1.13K ﹤0.01% 1098

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Winslow Evans & Crocker's AXDX Position: Q4 2020 in Review

Winslow Evans & Crocker opened a new position in Accelerate Diagnostics (AXDX) in Q4 2020: 118 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #959 among its holdings. This is a return to the name: Winslow Evans & Crocker previously reported a position in AXDX as recently as Q1 2019.

Winslow Evans & Crocker first reported a position in AXDX in Q1 2019 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold AXDX as of Q4 2020.

  • Winslow Evans & Crocker held 118 shares of Accelerate Diagnostics worth $9K as of Q4 2020.
  • Accelerate Diagnostics was a new Winslow Evans & Crocker position in Q4 2020.
  • Accelerate Diagnostics made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #959 holding.
  • Winslow Evans & Crocker first reported a position in Accelerate Diagnostics in Q1 2019 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.